Literature DB >> 10751801

Management of Acute Ischemic Coronary Syndromes: The Present and Future.

.   

Abstract

This article begins by discussing the pathogenesis of acute ischemic syndromes reviewing the cascade of ischemic events. We then go on to discuss the interventional management of acute ischemic syndromes and the benefits of early conservative therapy versus aggressive management with either PTCA or stenting. A discussion is then held regarding the pharmacological management of acute ischemic syndromes including the various agents involved including thrombolytic agents, aspirin, heparin and other measures. The main body of the article reviews the role of the 2B/3A inhibitors and the management of acute ischemic syndromes, including those studies that have been conducted to date, reviewing the role of the 2B/3A inhibitors and acute ischemic syndromes and the outcome from their application.

Entities:  

Year:  1998        PMID: 10751801     DOI: 10.1023/A:1008878628326

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  127 in total

Review 1.  Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

Authors:  R A Harrington
Journal:  Am J Cardiol       Date:  1997-08-18       Impact factor: 2.778

2.  Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms.

Authors:  R M Scarborough; J W Rose; M A Naughton; D R Phillips; L Nannizzi; A Arfsten; A M Campbell; I F Charo
Journal:  J Biol Chem       Date:  1993-01-15       Impact factor: 5.157

Review 3.  Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.

Authors:  E M Ohman; R A Harrington; A M Lincoff; M M Kitt; N S Kleiman; J E Tcheng
Journal:  Eur Heart J       Date:  1995-11       Impact factor: 29.983

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

5.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

Authors:  N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

6.  Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups.

Authors:  R J Gibbons; D R Holmes; G S Reeder; K R Bailey; M R Hopfenspirger; B J Gersh
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

7.  Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group.

Authors:  J M Sutton; S G Ellis; G S Roubin; C A Pinkerton; S B King; A E Raizner; D R Holmes; D J Kereiakes; E J Topol
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

8.  Nitrates in myocardial infarction: a current perspective.

Authors:  J L Morris; J C Cowan
Journal:  Can J Cardiol       Date:  1995-04       Impact factor: 5.223

9.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.

Authors:  U Sigwart; J Puel; V Mirkovitch; F Joffre; L Kappenberger
Journal:  N Engl J Med       Date:  1987-03-19       Impact factor: 91.245

Review 10.  Heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.